Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target? - ScienceDirect

The Lancet Oncology

Volume 19, Issue 5, May 2018, Pages 591-592

The Lancet Oncology

https://doi.org/10.1016/S1470-2045(18)30249-3 Get rights and content

References (9)

L Rimassa et al.
Tivantinib for second-line treatment of advanced MET-high hepatocellular carcinoma (METIV-HCC): a phase 3, randomised, placebo-controlled study
Lancet Oncol
(2018)
A Santoro et al.
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Lancet Oncol
(2013)
I Watermann et al.
Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
Diagn Pathol
(2015)
JH Kim et al.
Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review
Oncotarget
(2017)

There are more references available in the full text version of this article.

Cited by (12)

Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021
2022, Expert Opinion on Investigational Drugs
Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
2021, Frontiers in Immunology
Response to crizotinib in a patient with MET-amplified hepatocellular carcinoma
2021, Hepatology Research
MET canonical transcript expression is a predictive biomarker for chemo-sensitivity to MET-inhibitors in hepatocellular carcinoma cell lines
2021, Journal of Cancer Research and Clinical Oncology
Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non-small-cell lung cancer: A meta-analysis based on randomized controlled trials
2020, Medicine (United States)
Hepatocellular carcinoma
2019, Oncology in the Precision Medicine Era: Value-Based Medicine

View all citing articles on Scopus

© 2018 Elsevier Ltd. All rights reserved.